WorldHeart expands bridge-to-transplant Levacor trial
This article was originally published in Clinica
Executive Summary
WorldHeart has received approval from the US FDA to add 10 more clinical sites to an ongoing trial of its ventricular assist device, Levacor. The pivotal bridge-to-transplant study will now enrol patients at 20 sites. Salt Lake City, Utah-based WorldHeart began the trial in January (www.clinica.co.uk, 11 January 2010). Levacor is the only fully magnetically levitated, bearingless, implantable centrifugal pump to move into clinical trials, the company claims. The study's expansion comes after leading cardiovascular centres and clinicians "expressed strong interest" in the product, WorldHeart added.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.